Component information
No US or EU label exists for this exact combination, so information is shown for each component.
Use: Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in… US FDA label
Use: INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of Gentamicin Sulfate in 0.9% Sodium Chloride Injection and other antibacterial drugs, Gentamicin Sulfate in 0.9%… US FDA label
Kidney dosing: Gentamicin (single-agent)Show full dosing details
- CrCl ≥60 mL/min
- Normal kidney function: 3 mg/kg/day in 3 doses every 8 hours; up to 5 mg/kg/day for life-threatening infection, reduced as soon as possible. Obese patients: dose by lean body mass. Measure peaks (4 to 6 mcg/mL) and troughs (label). Alternative (not in label): extended-interval dosing, e.g., 7 mg/kg with interval by CrCl (≥60: every 24 h; 40–59: every 36 h; 20–39: every 48 h) and a single-level nomogram (Nicolau 1995). Not validated below CrCl 20 or on dialysis: use the label method with levels.
- CrCl 30–59 mL/min
- After the usual first dose, either extend the interval (hours = serum creatinine in mg/dL × 8) or keep 8-hourly doses reduced by the label's serum creatinine table (Table 4) or by dividing the normal dose by serum creatinine. Avoid prolonged peaks above 12 mcg/mL and troughs above 2 mcg/mL; measure levels (label). Table 4 examples: CrCl about 40–45 (SCr 2–2.2): 50%; 30–35 (SCr 2.6–3): 35% of the usual dose every 8 hours. Alternative (not in label): extended-interval dosing, e.g., 7 mg/kg with interval by CrCl (≥60: every 24 h; 40–59: every 36 h; 20–39: every 48 h) and a single-level nomogram (Nicolau 1995). Not validated below CrCl 20 or on dialysis: use the label method with levels. In AKI, creatinine lags; the label warns that deteriorating kidney function needs a greater reduction than these tables.
- CrCl 15–29 mL/min
- After the usual first dose, either extend the interval (hours = serum creatinine in mg/dL × 8) or keep 8-hourly doses reduced by the label's serum creatinine table (Table 4) or by dividing the normal dose by serum creatinine. Avoid prolonged peaks above 12 mcg/mL and troughs above 2 mcg/mL; measure levels (label). Table 4 example: CrCl about 20–25: 25%; 15–20: 20% of the usual dose every 8 hours. Alternative (not in label): extended-interval dosing, e.g., 7 mg/kg with interval by CrCl (≥60: every 24 h; 40–59: every 36 h; 20–39: every 48 h) and a single-level nomogram (Nicolau 1995). Not validated below CrCl 20 or on dialysis: use the label method with levels. In AKI, creatinine lags; the label warns that deteriorating kidney function needs a greater reduction than these tables.
- CrCl <15 mL/min (not on dialysis)
- After the usual first dose, either extend the interval (hours = serum creatinine in mg/dL × 8) or keep 8-hourly doses reduced by the label's serum creatinine table (Table 4) or by dividing the normal dose by serum creatinine. Avoid prolonged peaks above 12 mcg/mL and troughs above 2 mcg/mL; measure levels (label). Table 4: CrCl about 10–15: 15%; under 10: 10% of the usual dose every 8 hours. Specialist input. In AKI, creatinine lags; the label warns that deteriorating kidney function needs a greater reduction than these tables.
- Hemodialysis (intermittent)
- 1 to 1.7 mg/kg at the end of each dialysis, depending on severity of infection; an 8-hour hemodialysis lowers levels by about 50% (label). Check levels.
- Peritoneal dialysis
- No PD dose in label; removal by peritoneal dialysis is much slower than by hemodialysis. For PD-associated peritonitis (ISPD 2022): 0.6 mg/kg intraperitoneally once daily, intermittent (in one exchange daily with a dwell of at least 6 hours); continuous dosing is not advised. Check levels; specialist input.
- CRRT
- No data in label, and gentamicin is not in the Li 2020 CRRT table. Level-guided dosing with specialist input.
- Dialyzable? Yes by hemodialysis (about 50% over 8 hours; label); much less by peritoneal dialysis. Protein binding 0% to 30%.
- Monitoring Peak and trough levels; serum creatinine before and during therapy; urinalysis; hearing and vestibular function; magnesium, calcium and potassium (wasting, Fanconi-like syndrome reported). Avoid other nephrotoxic drugs and potent diuretics.
From the Gentamicin monograph (renalcarematters.com, reviewed).
Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney dosing for each component (single-agent) is shown under Component information.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- Per ml ophthalmic solution: 3 mg/1 mg
Registered products in the Philippines
1 product registered with the Food and Drug Administration (FDA) Philippines list Dexamethasone + Gentamicin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
OptagenGentamicin (as sulfate) + Dexamethasone (as sodium phosphate) | 3 mg/1 mg per mL Ophthalmic SolutionLDPE Plastic Bottle x 5 mL (Box of 1's and 10's) | Rx | Amanta Healthcare Ltd.India | Endure Medical, Inc. | DR-XY41926 | Apr 18, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .